Revvity, Inc. (RVTY) Enterprise Value (EV): $13.36B
The enterprise value (EV) for Revvity, Inc. (RVTY) is $13.36B as of Wednesday, June 17, 2026.
RVTY Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$13.36B
RVTY Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Revvity, Inc. (RVTY) | $10.91B | $13.36B |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | $40.43B |
| Baxter International Inc. (BAX)vs › | $10.19B | $17.84B |
| Align Technology, Inc. (ALGN)vs › | $12.43B | $10.36B |
| The Cooper Companies, Inc. (COO)vs › | $12.69B | $16.66B |
| Solventum Corporation (SOLV)vs › | $12.91B | $17.95B |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.78B | $12.95B |
| Medpace Holdings, Inc. (MEDP)vs › | $13.05B | $15.95B |
| Tempus AI, Inc. (TEM)vs › | $8.51B | $11.01B |
| DaVita Inc. (DVA)vs › | $13.52B | $24.07B |
Enterprise Value Calculation
Market Cap
$10.91B
Total Debt
$3.37B
Cash
$919.87M
Enterprise Value
$13.36B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
Revvity, Inc. Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Revvity, Inc. Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for Revvity, Inc. (RVTY)?
- The enterprise value (EV) for RVTY stock is $13.36B.
Related Metrics
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh